The present invention provides a method for treating an ocular disease or condition in a subject, comprising administering to the subject’s ocular tissue a composition comprising an effective amount of one or more bioactive agents, wherein the composition is administered with a single-chamber or multi-chamber microchannel delivery device.

Disclosed herein are compositions and in vitro and in vivo methods for reprogramming post-natal (adult and juvenile) tissue into insulinogenic cells. These compositions and methods are useful for a variety of purposes, including the development of diabetes therapies.

A drug injection device contains a needle holder, an ejector, a needle member, and an actuation assembly. The needle holder defines a drug delivery direction extending toward the injection end. The ejector contains a fixing segment that is fixed to the needle holder and located in the drug delivery direction, and the abutting segment extending toward the injection end and protruding beyond the needle holder. The needle member is movably arranged relative to the needle holder and contains a needle shaft connected to a needle hub coaxially arranged with the ejector for the abutting segment inserting into the needle shaft. The actuator assembly connects the needle holder and the needle shaft for driving the needle member between a first position and a second position with respect to the needle holder.

Provided herein are fluid formulations for administration to a suprachoroidal space of an eye of a patient. The fluid formulations may include a pharmaceutical agent, a binding molecule, or a combination thereof. The pharmaceutical agent and the binding molecule may be bonded to each other covalently, non-covalently, or a combination thereof. The pharmaceutical agent may be configured to bond to an ocular tissue. The binding molecule may be configured to bond to an ocular tissue. Methods of administering the fluid formulations, methods of expanding a suprachoroidal space, and methods of reducing the minimum force to separate the sclera and choroid are provided.

A medical liquid injection device including a catheter with a hollow shaft having a lumen formed inside to contain medical liquid, a wire to be inserted into the lumen, and a wire moving device to move the wire forward inside the lumen from a proximal end to a distal end side in accordance with a control signal, thereby ejecting a predetermined amount of the medical liquid from the distal end of the hollow shaft.

Provided herein are fluid formulations for administration to a suprachoroidal space of an eye of a patient. The fluid formulations may include a pharmaceutical agent, a binding molecule, or a combination thereof. The pharmaceutical agent and the binding molecule may be bonded to each other covalently, non-covalently, or a combination thereof. The pharmaceutical agent may be configured to bond to an ocular tissue. The binding molecule may be configured to bond to an ocular tissue. Methods of administering the fluid formulations, methods of expanding a suprachoroidal space, and methods of reducing the minimum force to separate the sclera and choroid are provided.

Methods for using precision low-dose, low-waste syringe configurations, which may have a reduced diameter lumen for dispensing 0.01 ml increments of contents. Methods may employ ergonomic attachments that improve the control and precision of the syringe. An attachment main body includes a gripping surface to permit a user to engage the attachment and move the attachment main body, and thus the syringe plunger relative to the syringe barrel using sliding movement. Methods may employ an assist feature on the attachment, which may be a traction wheel. Methods for using syringes with contents of higher viscosity may employ a pair of toothed pinion gears on a wheel and which cooperate with respective toothed racks formed on or fastened to the syringe body.

A method of preparing a syringe in connection with a therapeutic treatment is disclosed. The method can include removing a plunger of the syringe from a barrel of the syringe, aligning the barrel in a horizontal orientation, filling a lumen of the barrel with a viscous material through an opening at a proximal end of the barrel, and inserting a plunger tip into the lumen to seal the lumen. The method can also include attaching an implantation device to a hub coupled to the barrel at a distal end of the barrel. The method can also include depressing the plunger until the cell suspension fills the implantation device and a droplet of the cell suspension is expelled from a distal tip of the implantation device.

A wearable drug delivery device that can deliver a liquid drug stored in a container to a patient is provided. The container can be a prefilled cartridge that can be loaded into the drug delivery device by the patient or that can be preloaded within the drug delivery device when provided to the patient. A sealed end of the container is pierced to couple the stored liquid drug to a needle conduit that is coupled to a needle insertion component that provides access to the patient. A drive system of the drug delivery device can expel the liquid drug from the cartridge to the patient through the needle conduit. The drive system can be controlled to provide the liquid drug to the patient in a single dose or over multiple doses.

A needle assembly includes: a needle comprising a hollow needle tube, a needle tip at a distal end of the hollow needle tube, and a cutting face disposed adjacent to the needle tip; and a needle hub that includes a tip and a base end, and holds the needle at the needle tip. The needle hub includes a needle tip side end face from which the needle tip projects. An outer diameter of the needle is within a range of 0.15 mm to 0.20 mm, inclusive. A projection needle length extending from the needle tip side end face to the needle tip is within a range of 0.50 mm to 1.25 mm, inclusive. A needle body length extending from the needle tip side end face to a proximal end of the cutting face in within a range of 0.10 mm to 0.70 mm, inclusive.